Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan.
D049673:History, 20th Century; D006689:Hodgkin Disease / Q000188:drug therapy / Q000266:history; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000266:history; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000266:history; D008466:Mechlorethamine / Q000266:history / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000266:history; D009588:Nitrogen Mustard Compounds / Q000266:history* / Q000627:therapeutic use; D014481:United States
D009588:Nitrogen Mustard Compounds; D008466:Mechlorethamine; C009802:2,2',2''-trichlorotriethylamine